(Q40295389)

English

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).

scientific article published on 20 November 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

19 September 2017

Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID). (English)

1 reference

Europe PubMed Central

19 September 2017

neuromyelitis optica

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

P S Rommer

1

1 reference

Europe PubMed Central

19 September 2017

T Dörner

2

1 reference

Europe PubMed Central

19 September 2017

K Freivogel

3

1 reference

Europe PubMed Central

19 September 2017

J Haas

4

1 reference

Europe PubMed Central

19 September 2017

B C Kieseier

5

1 reference

Europe PubMed Central

19 September 2017

T Kümpfel

6

1 reference

Europe PubMed Central

19 September 2017

F Paul

7

1 reference

Europe PubMed Central

19 September 2017

F Proft

8

1 reference

Europe PubMed Central

19 September 2017

H Schulze-Koops

9

1 reference

Europe PubMed Central

19 September 2017

E Schmidt

10

1 reference

Europe PubMed Central

19 September 2017

U Ziemann

12

1 reference

Europe PubMed Central

19 September 2017

U K Zettl

13

1 reference

Europe PubMed Central

19 September 2017

GRAID investigators

14

1 reference

Europe PubMed Central

19 September 2017

H Wiendl

11

1 reference

Europe PubMed Central

19 September 2017

publication date

20 November 2015

1 reference

Europe PubMed Central

19 September 2017

Journal of Neuroimmune Pharmacology

1 reference

Europe PubMed Central

19 September 2017

11

1 reference

Europe PubMed Central

19 September 2017

1

1 reference

Europe PubMed Central

19 September 2017

1-8

1 reference

Europe PubMed Central

19 September 2017

https://scigraph.springernature.com/pub.10.1007/s11481-015-9646-5

0 references

Rituximab use in pediatric central demyelinating disease

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

The potential role of B cell-targeted therapies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

An open label study of the effects of rituximab in neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

MS and the B cell controversy

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

The off-label use of targeted therapies in sarcomas: the OUTC'S program

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Neuromyelitis optica: clinical features, immunopathogenesis and treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Registers of multiple sclerosis in Denmark

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

B cells in MS and NMO: pathogenesis and therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Pathology of multiple sclerosis and related inflammatory demyelinating diseases

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Multiple sclerosis: a complicated picture of autoimmunity.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Multiple sclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Management of secondary progressive multiple sclerosis: prophylactic treatment-past, present, and future aspects

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Monoclonal antibodies in the treatment of neuroimmunological diseases

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Requirement for safety monitoring for approved multiple sclerosis therapies: an overview

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Immunopathogenic mechanisms of systemic autoimmune disease

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

The clinical course of neuromyelitis optica (Devic's syndrome).

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Revised diagnostic criteria for neuromyelitis optica

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Immune-mediated CNS diseases: a review on nosological classification and clinical features

1 reference

https://api.crossref.org/works/10.1007%2FS11481-015-9646-5

21 January 2018

Association between disease activity and risk of serious infections in subjects with rheumatoid arthritis treated with etanercept or disease-modifying anti-rheumatic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spotlight on anti-CD20.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab for secondary progressive multiple sclerosis: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab for relapsing-remitting multiple sclerosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

BIOBADASER, BIOBADAMERICA, and BIOBADADERM: safety registers sharing commonalities across diseases and countries.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic plasma exchange in glucocorticosteroid-unresponsive patients with Clinically Isolated Syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

1 reference

https://pubmed.ncbi.nlm.nih.gov/26589235

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11481-015-9646-5

1 reference

Europe PubMed Central

19 September 2017

1 reference

Europe PubMed Central

19 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40295389&oldid=1900314597"